Collegium Pharmaceutical, Inc. (COLL)
USD 25.41
(-7.2%)
USD 25.41
(-7.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 489.96 Million USD | -30.91% |
| 2022 | 709.17 Million USD | 174.08% |
| 2021 | 258.75 Million USD | -2.94% |
| 2020 | 266.58 Million USD | 1134.53% |
| 2019 | 21.59 Million USD | 119.05% |
| 2018 | 9.85 Million USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 1.47 Million USD | -64.33% |
| 2015 | 4.14 Million USD | -39.15% |
| 2014 | 6.81 Million USD | 964.53% |
| 2013 | 640 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 369.49 Million USD | -15.98% |
| 2024 Q1 | 439.78 Million USD | -10.24% |
| 2023 Q4 | 489.96 Million USD | -8.26% |
| 2023 Q1 | 621.86 Million USD | -12.31% |
| 2023 Q2 | 578.04 Million USD | -7.05% |
| 2023 Q3 | 534.09 Million USD | -7.6% |
| 2023 FY | 489.96 Million USD | -30.91% |
| 2022 Q2 | 632.86 Million USD | -6.45% |
| 2022 Q1 | 676.49 Million USD | 161.45% |
| 2022 FY | 709.17 Million USD | 174.08% |
| 2022 Q4 | 709.17 Million USD | 20.35% |
| 2022 Q3 | 589.24 Million USD | -6.89% |
| 2021 Q2 | 233.82 Million USD | -4.9% |
| 2021 Q1 | 245.86 Million USD | -7.77% |
| 2021 FY | 258.75 Million USD | -2.94% |
| 2021 Q4 | 258.75 Million USD | 16.69% |
| 2021 Q3 | 221.73 Million USD | -5.17% |
| 2020 Q1 | 249.35 Million USD | 1054.75% |
| 2020 Q2 | 238.99 Million USD | -4.16% |
| 2020 Q3 | 228.72 Million USD | -4.3% |
| 2020 Q4 | 266.58 Million USD | 16.55% |
| 2020 FY | 266.58 Million USD | 1134.53% |
| 2019 Q2 | 19.48 Million USD | 1.88% |
| 2019 FY | 21.59 Million USD | 119.05% |
| 2019 Q4 | 21.59 Million USD | 18.41% |
| 2019 Q3 | 18.23 Million USD | -6.41% |
| 2019 Q1 | 19.12 Million USD | 94.03% |
| 2018 Q3 | 10.67 Million USD | -7.14% |
| 2018 Q4 | 9.85 Million USD | -7.69% |
| 2018 Q2 | 11.5 Million USD | 0.0% |
| 2018 FY | 9.85 Million USD | 0.0% |
| 2018 Q1 | 11.5 Million USD | 0.0% |
| 2017 Q1 | 924 Thousand USD | -37.53% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | 424 Thousand USD | -54.11% |
| 2017 FY | - USD | -100.0% |
| 2016 Q4 | 1.47 Million USD | -31.08% |
| 2016 Q3 | 2.14 Million USD | -23.71% |
| 2016 Q2 | 2.81 Million USD | -19.17% |
| 2016 Q1 | 3.48 Million USD | -16.06% |
| 2016 FY | 1.47 Million USD | -64.33% |
| 2015 Q2 | 5.48 Million USD | -10.84% |
| 2015 Q4 | 4.14 Million USD | -13.86% |
| 2015 FY | 4.14 Million USD | -39.15% |
| 2015 Q3 | 4.81 Million USD | -12.17% |
| 2015 Q1 | 6.14 Million USD | -9.79% |
| 2014 FY | 6.81 Million USD | 964.53% |
| 2014 Q4 | 6.81 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2013 FY | 640 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Journey Medical Corporation | 14.62 Million USD | -3250.855% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -58.221% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -437.97% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 4.639% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -90796.138% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -90796.138% |
| SCYNEXIS, Inc. | 12.15 Million USD | -3929.624% |
| Safety Shot Inc | 304.9 Thousand USD | -160592.277% |
| Alpha Teknova, Inc. | 13.25 Million USD | -3597.547% |
| Bright Green Corporation | 201.78 Thousand USD | -242716.293% |
| Dynavax Technologies Corporation | 252.41 Million USD | -94.107% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 2.31% |
| Cosmos Health Inc. | 3.03 Million USD | -16041.91% |
| PainReform Ltd. | 30 Thousand USD | -1633106.667% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -418209.727% |
| Embecta Corp. | 1.62 Billion USD | 69.856% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -3576.737% |
| Procaps Group, S.A. | 28.41 Million USD | -1624.611% |
| Theratechnologies Inc. | 51.26 Million USD | -855.818% |
| Harrow Health, Inc. | 183.17 Million USD | -167.487% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -563074.713% |
| Biofrontera Inc. | 804 Thousand USD | -60840.547% |
| DURECT Corporation | 2.7 Million USD | -18033.309% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1375.967% |
| Cronos Group Inc. | 1.55 Million USD | -31327.967% |
| OptiNose, Inc. | 611 Thousand USD | -80090.18% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 1.675% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1333.056% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -107583.956% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -706.588% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -3732.576% |
| Radius Health, Inc. | 339.66 Million USD | -44.249% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -4676.389% |
| Phibro Animal Health Corporation | 458.28 Million USD | -6.911% |
| Procaps Group S.A. | 28.41 Million USD | -1624.611% |
| Alvotech | 1.02 Billion USD | 52.327% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -7400.949% |
| Viatris Inc. | 16.18 Billion USD | 96.973% |
| Rockwell Medical, Inc. | 8.29 Million USD | -5808.14% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -4404.569% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -145725.93% |
| Tilray Brands, Inc. | 287.93 Million USD | -70.164% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -306.574% |
| Shineco, Inc. | 10.01 Million USD | -4791.143% |
| PetIQ, Inc. | 437.82 Million USD | -11.909% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -233215.238% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -89.687% |
| Alimera Sciences, Inc. | 64.48 Million USD | -659.761% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1172.166% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -362595.704% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -7045.049% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -67950.278% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2179058.513% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1395.611% |
| Hempacco Co., Inc. | 5.93 Million USD | -8161.034% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 52.327% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -771.57% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 20.477% |
| Currenc Group, Inc. | 2.5 Million USD | -19443.96% |
| Kamada Ltd. | 7.43 Million USD | -6487.282% |
| Indivior PLC | 235.66 Million USD | -107.905% |
| Evoke Pharma, Inc. | 5 Million USD | -9699.24% |
| Flora Growth Corp. | 942 Thousand USD | -51912.951% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2179058.513% |
| Evolus, Inc. | 120.35 Million USD | -307.084% |
| HUTCHMED (China) Limited | 48.18 Million USD | -916.751% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 16.843% |
| Akanda Corp. | 2.49 Million USD | -19520.808% |